Pharma & Biotech
-
Malvern Medical Device Company Chooses New CEO Months After Emerging from Bankruptcy
Malvern’s LifeScan has a new CEO after emerging from bankruptcy at the end of 2025. Last week, Jonathan Salkin took over to lead the company, writes John George for the Philadelphia Business Journal. LifeScan filed for Chapter 11 bankruptcy in July 2025, and through its reorganization plan, eliminated over 75 percent of its debt. Former…
-
West Conshohocken’s Madrigal Pharmaceuticals Eyes $1B Expansion Deal
Madrigal Pharmaceuticals is making another major move in the rapidly growing liver disease treatment market, writes John George for The Philadelphia Business Journal. The West Conshohocken company has a potential $1 billion licensing agreement aimed at expanding its pipeline of therapies for MASH. Madrigal announced it will pay California-based Arrowhead Pharmaceuticals $25 million upfront for…
-
Malvern Gene Company to Raise $115M from Convertible Notes While Dealing with Stock Decline
Malvern-based Ocugen saw its stock fall almost 20 percent after an announcement to use convertible notes to pay down existing debt and fund ongoing drug development, writes John George for the Philadelphia Business Journal. The gene therapy company plans to raise $115 million through these notes, which is debt that be turned into stock. The…
-
Radnor Drug Designer Certara Sells Medical Writing Business
Radnor-based drug developer Certara is selling its regulatory and medical writing business for up to $135 million to Veristat, writes John George for Philadelphia Business Journal. The medical writing business prepares official documents needed to get drugs approved. Veristat provides outsourced research and development services to help bring drugs and therapies to market. An agreement…
-
Conshohocken’s Cencora Prepares for Leadership Change This Summer
Conshohocken’s Cencora is preparing for a major leadership transition as executive vice president and chief financial officer James Cleary plans to step down, writes Sydney Halleman for HealthCareDive. The company said Cleary will officially step down on June 30, but will remain with Cencora through the end of the year in an advisory capacity as…
-
Montco Vaccine Maker Bets Its Data May Be Worth as Much as Its Science
Ambler’s MBF Therapeutics believes the data behind its vaccines could become just as valuable as the vaccines themselves, writes Holly Quinn for Technical.ly. The company has spent more than a decade developing a non-viral vaccine platform for animal health. According to CEO and cofounder Tom Tillett, MBF is exploring whether its detailed immune-response data could…
-
KJ’s ‘Thriving’ a Year After Gene Editing Therapy Treats Rare Disease
It’s been a year since KJ, a Clifton Heights infant, received the world’s first personalized gene editing therapy to treat his rare disease. KJ Muldoon was born with CPS1 Deficiency, a life-threatening condition that prevents his liver from processing protein. This can lead to a buildup of toxic levels of ammonia in the blood. “You…
-
Madrigal’s Rezdiffra Nears Blockbuster Status With $958M in First Full Year on Market
In its first full year on the market, West Conshohocken-based Madrigal Pharmaceuticals’ flagship drug Rezdiffra nearly got to blockbuster status, bringing in $958.4 million in 2025, writes John George for the Philadelphia Business Journal. The treatment for MASH, a progressive liver disease metabolic dysfunction-associated steatohepatitis, marked the company’s largest advancement since being founded in 2011.…
-
Conshohocken’s Cencora Strikes $3.5B Animal Health Deal
Conshohocken’s Cencora is reshaping its business with a $3.5 billion deal involving its animal health division, writes John George for The Philadelphia Business Journal. The wholesale drug distributor announced it will combine MWI Animal Health with Maine-based Covetrus, creating a newly merged company focused exclusively on animal health technology and distribution. In return, Cencora will…
-
Doylestown’s Aprea Therapeutics Names Industry Veteran as Chief Medical Advisor
Doylestown-based Aprea Therapeutics has named Eugene Kennedy, MD, as chief medical advisor, adding a seasoned leader in oncology drug development to its executive team. Aprea is a clinical-stage biopharmaceutical company advancing innovative therapies targeting cancer-specific vulnerabilities while minimizing damage to healthy cells. Kennedy joins after early clinical proof-of-concept was demonstrated for the WEE1 inhibitor APR-1051…
-
Eli Lilly to Build $3.5B Weight-Loss Drug Plant in Upper Macungie
Eli Lilly plans to build a $3.5 billion pharmaceutical plant in Upper Macungie Township, just north of Montgomery County, for its next-generation weight-loss medicines, writes Harold Brubaker for The Philadelphia Inquirer. The selection of the Lehigh Valley for one of Eli Lilly’s four new U.S. factories represents a significant win for Pennsylvania as it competes…
-
Conshohocken-based Cencora’s New Partnership Speeds Rare Disease Treatment to Market
Conshohocken’s Cencora partnered with Curant Rare to help rare disease treatments reach patients faster and more smoothly, the companies announced in a press release. Curant Rare announced a strategic collaboration with Cencora to support pharmaceutical companies bringing rare disease therapies to market. Rare disease drugs often face added hurdles, including complex regulations and limited patient…
-
Nature Science Journal: Baby KJ in Clifton Heights Helped Shaped Medicine in 2025
A Clifton Heights infant named KJ Muldoon has made Nature Science Journal’s top 10 list of people who helped shape medicine in 2025, thanks to a frontline gene-editing treatment he received, writes Sarah Gantz for The Philadelphia Inquirer. CHOP and Penn are researching how to make his treatment available to more patients. KJ received international…
-
Yardley-Based Jubilant Therapeutics Appoints Industry Veteran as New CEO
Jubilant Therapeutics, a Yardley-based biopharmaceutical company focused on cancer and autoimmune disease treatments, has named Daniel J. O’Connor to be its new CEO, writes John George for the Philadelphia Business Journal. O’Connor brings with him more than thirty years of executive experience in the life sciences industry. He previously led Ambryx Biopharma, a San Diego…
-
Wayne Company Lands on Deloitte’s Fast 500
One Chester County company has earned a place on Deloitte’s 2025 list of the fastest-growing technology firms in North America, writes Ryan Mulligan for the Philadelphia Business Journal. Deloitte released its 31st annual Technology Fast 500 earlier this week, ranking public and private tech companies based on revenue growth from 2021 through 2024. Aclaris Therapeutics…
-
CSL to Invest $1.5B in U.S. Growth Amid Restructuring and Local Layoffs
CSL, which has major operations in King of Prussia, announced plans to expand in the U.S., reports John George for the Philadelphia Business Journal. The Australian biopharmaceutical company plans to invest roughly $1.5 billion in its footprint over the next five years. Company leaders said the expansion will strengthen domestic manufacturing of plasma-derived therapies and…
-
Orchestra Life Sciences Headquarters Moving from Canada to Philadelphia Navy Yard with Planned Expansion
Orchestra Life Sciences is moving its headquarters from Montreal in Canada, to the Philadelphia Navy Yard as it prepares for rapid growth, writes John George for the Philadelphia Business Journal. The firm, which supports pharmaceutical and biotechnology companies developing therapies for cancer and rare diseases, currently has more than 60 employees around the world and…
-
Merck Finalizes $10 Billion Acquisition, Expands COPD Treatment Portfolio
Pharmaceutical giant Merck, which maintains major operations in Montgomery County, has completed its $10 billion acquisition of Verona Pharma, writes the New Jersey Business and Industry Association. The acquisition strengthens its cardio-pulmonary treatment lineup with the addition of Ohtuvayre, a breakthrough therapy for chronic obstructive pulmonary disease (COPD). Verona Pharma now operates as a wholly…
Founding Partners
Advertisement
Affiliate Partners
Chamber Partners
